TSE:HBP Helix BioPharma (HBP) Stock Price, News & Analysis C$1.87 +0.07 (+3.89%) As of 02:47 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Helix BioPharma Stock (TSE:HBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Helix BioPharma alerts:Sign Up Key Stats Today's RangeC$1.78▼C$1.9450-Day RangeC$1.33▼C$1.8752-Week RangeC$1.10▼C$5.40Volume3,228 shsAverage Volume2,161 shsMarket CapitalizationC$142.83 millionP/E RatioN/ADividend Yield1.50%Price TargetN/AConsensus RatingN/A Company Overview Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA¿, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA¿, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers. Read More Receive HBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBP Stock News HeadlinesHelix BioPharma Reshapes Board to Align with Oncology Growth StrategyAugust 14 at 6:11 PM | tipranks.comHelix BioPharma (TSE:HBP) Stock Price Passes Above Fifty Day Moving Average - What's Next?August 13 at 4:01 AM | americanbankingnews.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.August 14 at 1:00 AM | Paradigm Press (Ad)Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical DevelopmentJune 30, 2026 | finance.yahoo.comHelix BioPharma Showcases CEACAM6-Targeted ADC Advances at World ADC LondonFebruary 24, 2026 | tipranks.comHelix BioPharma Extends LEUMUNA Option with metaShape in Metabolic Disease PushFebruary 5, 2026 | tipranks.comHelix BioPharma Shareholders Back Board, Auditor and Share Consolidation PlanJanuary 30, 2026 | tipranks.comHelix BioPharma Reports Fiscal 2025 Results and Strategic DevelopmentsOctober 29, 2025 | tipranks.comSee More Headlines HBP Stock Analysis - Frequently Asked Questions How have HBP shares performed this year? Helix BioPharma's stock was trading at C$2.37 on January 1st, 2026. Since then, HBP stock has decreased by 21.1% and is now trading at C$1.87. How were Helix BioPharma's earnings last quarter? Helix BioPharma Corp. (TSE:HBP) released its quarterly earnings results on Friday, June, 12th. The biopharmaceutical company reported ($0.01) EPS for the quarter. How do I buy shares of Helix BioPharma? Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Helix BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU). Company Calendar Last Earnings6/12/2026Today8/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolTSE:HBP CIKN/A Webwww.helixbiopharma.com Phone+1-416-9253232FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$50.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.54% Return on Assets-279.98% Debt Debt-to-Equity Ratio2.44 Current Ratio0.45 Quick Ratio1.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.17 per share Price / Cash Flow11.32 Book ValueC$0.19 per share Price / Book9.72Miscellaneous Outstanding Shares76,378,000Free FloatN/AMarket CapC$142.83 million OptionableNot Optionable Beta0.43 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (TSE:HBP) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersAI insiders stockpile guns, gold & gas masksKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe Shocking Discovery Investigators Found Hidden Inside America's Port CranesU.S. investigators found unexplained cellular modems inside cranes made by a Chinese state-owned company that ...Altimetry | SponsoredHow a rare metal shortage sent gains up 2512 percentIn 2010, a rare earth metal called dysprosium surged 2,512 percent in two and a half years after China cut exp...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
